You are here

CAR-T

J&J, Legend's Carvykti cut risk of progression or death by whopping 74% in earlier myeloma, leaked abstract shows

Fierce Pharma

Wed, 04/19/23 - 11:24 am

Bristol Myers Squibb

Multiple Myeloma

Caribou gets FDA fast track for allogeneic CAR-T

Biopharma Reporter

Tue, 04/11/23 - 10:02 am

Caribou Biosciences

Multiple Myeloma

Gilead’s Yescarta extends survival in lymphoma study

BioPharma Dive

Tue, 03/21/23 - 09:53 pm

Gilead Sciences

large B-cell lymphoma

Johnson & Johnson shelves Carvykti's UK launch amid manufacturing shortfalls

Fierce Pharma

Wed, 03/15/23 - 09:27 pm

Cancer drug startup Cargo raises $200M to solve CAR-T relapse

BioPharma Dive

Thu, 03/2/23 - 10:28 am

Cargo Therapeutics

OCI-led CAR-T leukemia therapy receives €2.5m from EIC

Pharmaphorum

Mon, 02/27/23 - 07:02 pm

Bristol Myers details landmark Abecma multiple myeloma data that ASH turned down

Fierce Pharma

Sun, 02/12/23 - 07:46 pm

Bristol Myers Squibb

Multiple Myeloma

Bristol Myers claims win with CAR-T therapy Breyanzi in leukemia

Endpoints

Thu, 01/26/23 - 05:09 pm

Bristol Myers Squibb

After years of back-and-forth, Gilead's CAR-T Yescarta sways England's cost watchdog NICE

Fierce Pharma

Thu, 01/26/23 - 10:40 am

Gilead Sciences

Kite swoops in to buy Carl June-founded Tmunity, gaining key to Penn's CAR-T research apparatus

Fierce Biotech

Tue, 12/20/22 - 11:17 am

Gilead Sciences

ASH: Novartis stays the course with cell therapy bet as competitors line up 'off-the-shelf' options

Fierce Biotech

Tue, 12/13/22 - 10:36 am

ASH: In next BCMA myeloma race, Gracell dazzles with 100% response rate as Pfizer, BMS place their bets

Fierce Biotech

Mon, 12/12/22 - 10:33 am

Multiple Myeloma

Bristol Myers Squibb

ASH: Bristol Myers bolsters Breyanzi's case in earlier lymphoma amid clash with Gilead

Fierce Pharma

Mon, 12/12/22 - 10:16 am

Bristol Myers Squibb

B-cell lymphoma

With Neogene buy and a CAR-T in the clinic, AstraZeneca builds up cell therapy 'library'

Fierce Biotech

Mon, 12/5/22 - 11:04 am

Neogene Therapeutics

Beam jumps back into off-the-shelf CAR-T race after FDA lifts clinical hold

Fierce Biotech

Fri, 12/2/22 - 11:03 am

Beam Therapeutics

clinical trials

Sana lays off 15%, trims pipeline to keep funding flowing to off-the-shelf CAR-Ts

Fierce Biotech

Wed, 11/30/22 - 10:43 am

Sana Biotechnology

Pulling back the curtain on AstraZeneca’s CAR-T work

EP Vantage

Fri, 11/18/22 - 10:23 am

Gilead dodges Supreme Court review—and a $1.2B fine—in CAR-T patent feud with Bristol Myers

Fierce Pharma

Mon, 11/7/22 - 05:48 pm

Gilead Sciences

Bristol Myers Squibb

Ash 2022 preview – Affimed and Aptose score

EP Vantage

Sun, 11/6/22 - 01:24 pm

Aptose Biosciences

Galapagos lays off 200 staff, drops kidney and fibrosis programs in renewed CAR-T push

Fierce Biotech

Fri, 11/4/22 - 11:01 am

Pages